Alto Neuroscience reports positive Phase 2a data for depression drug

May 4, 2026 8:03 AM

Alto Neuroscience Inc. (NYSE: ANRO) presented data from a Phase 2a trial of ALTO-207 in patients with major depressive disorder ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found